For US Healthcare Professionals
I am a
Ulcerative Colitis Specialist
CD64+ cells are the predominant source of IL-23 in UC. Cells not expressing CD64 may also contribute to IL-23 production but to a lesser extent.2,4
CD64=cluster of differentiation 64; IL-23=interleukin-23; MOA=mechanism of action.
References: 1. TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn’s and Colitis Organisation (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504. 3. Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohns Colitis. 2022;16(suppl 2):ii3-ii19. doi: 10.1093/ecco-jcc/jjac034 4. Krueger JG, Eyerich K, Kuchroo VK, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. doi: 10.3389/fimmu.2024.1331217 5. Steere B, Beidler C, Martin A, et al. Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23. J Pharmacol Exp Ther. 2023;387(2):180-187. doi: 10.1124/jpet.122.001512